Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly(NYSE ... a much more accelerated rate than Lilly's business as a whole. One of the primary drivers for Verzenio's ...
Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...
The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.
The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.
The guidance predicts sales growth of 32% for the year, and the management team ... Eli Lilly has a first-mover advantage and the supply to feed the massive demand for weight-loss drugs. So, one ...